Status:
TERMINATED
Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Crohn Disease-Associated Colorectal Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The inflammatory tumor micro-environment is a consequence and a driver of tumorogenesis. On one hand it promotes antitumor immune responses and on the other hand it favors development and progression ...
Eligibility Criteria
Inclusion
- · All the patients requiring an endoscopy within the framework of a colorectal cancer
- All the patients requiring a low digestive endoscopy within the framework of the diagnosis or of the follow-up of a colorectal cancer, realized in the CHU of Nice.
- Realization of a preliminary medical examination
- Obligation for all the patients to be affiliated to the Social Security
- Signature of the informed consent
Exclusion
- • Pushed acute severe of the disease defined by the score of Truelove and Witss or the score of Lichtiger \> 10 (cf appendix)
- severe endoscopic Hurts returning the practice of dangerous additional biopsies
- Disorders of the coagulation or the patient under anti-vitamin K, aspirin or clopidogrel.
- Patient presenting an unchecked renal, respiratory, hepatic or cardiac insufficiency
- Patient known positive HIV
- vulnerable People: pregnant or breast-feeding women (a pregnancy test will be realized), minors, adults under guardianship or guardianships, deprived of freedom
Key Trial Info
Start Date :
February 9 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2015
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02293811
Start Date
February 9 2015
End Date
December 15 2015
Last Update
March 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nice
Nice, Alpes-Maritimes, France, 06001